Contra-indicated in patients with a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days; severe hypertension not adequately controlled on antihypertensive therapy; major surgery within the preceding 6 weeks; history of stroke within 30 days or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb/IIIa inhibitor; or dependency on renal dialysis.

Please login to view the rest of this drug profile.

    DRUG REVIEW ARTICLE

    Click on the DRUG REVIEW ARTICLE tab (above) to see a review of eptifibatide in the Taylor & Francis journal Expert Opinion on Drug Safety.

    (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 03/31/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric